MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
1097.75%
Quick Ratio
1097.75%
Cash Ratio
494.08%
Debt to Asset Ratio
42.06%
Unit: Thousand (K) dollars
Assets Breakdown
    • Short-term marketable securities
    • Cash and cash equivalents
    • Other non-current assets
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Royalty obligation - related par...
    • Others
Balance Sheets
2026-06-30
2025-12-31
2025-09-30
2025-06-30
Cash and cash equivalents
43,173
98,054
42,387
88,426
Short-term marketable securities
50,365
19,928
34,612
-
Deferred transaction costs
514
-
-
-
Prepaid expenses and other current assets
1,869
827
1,184
3,225
Total current assets
95,921
118,809
78,183
91,651
Deferred transaction costs
-
0
0
0
Operating lease right-of-use assets
1,389
1,475
1,516
-
Restricted cash
500
499
500
500
Other non-current assets
1,729
953
976
691
Total assets
99,539
121,736
81,175
92,842
Derivative liabilities (including 0 and 995 due to a related party)
-
0
0
0
Convertible promissory notes, net of discount of 1,298 (including 0 and 18,670 due to a related party)
-
0
0
0
Accounts payable
1,124
1,281
494
3,680
Tranche liability (including 0 and 331 due to a related party)
-
0
0
0
Accrued expenses and other current liabilities (including 40 and 67 due to a related party)
7,267
8,117
5,195
3,971
Operating lease liabilities, current
347
316
376
-
Total current liabilities
8,738
9,714
6,065
7,651
Royalty obligation - related party
32,076
32,076
32,076
32,076
Operating lease liabilities, long-term
1,053
1,132
1,169
-
Total liabilities
41,867
42,922
39,310
39,727
Common stock, 0.0001 and 0.0001 par value as of june 30, 2026 and december 31, 2025, respectively 300,000,000 shares authorized as of june 30, 2026 and december 31, 2025 23,804,981 and 22,902,418 shares issued and outstanding as of june 30, 2026 and december 31, 2025, respectively
2
2
2
2
Additional paid-in capital
240,113
238,805
191,858
191,220
Accumulated other comprehensive income (loss)
-73
6
6
-
Accumulated deficit
-182,370
-159,999
-150,001
-138,107
Total stockholders' equity
57,672
78,814
41,865
53,115
Total liabilities and stockholders' equity
99,539
121,736
81,175
92,842
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Short-term marketablesecurities$50,365K Cash and cashequivalents$43,173K (-51.18%↓ Y/Y)Prepaid expenses andother current assets$1,869K (-42.05%↓ Y/Y)Deferred transactioncosts$514K Total current assets$95,921K (4.66%↑ Y/Y)Other non-currentassets$1,729K (150.22%↑ Y/Y)Operating leaseright-of-use assets$1,389K Restricted cash$500K (0.00%↑ Y/Y)Total assets$99,539K (7.21%↑ Y/Y)Total liabilities andstockholders' equity$99,539K (7.21%↑ Y/Y)Total stockholders'equity$57,672K (8.58%↑ Y/Y)Total liabilities$41,867K (5.39%↑ Y/Y)Accumulated deficit-$182,370K (-32.05%↓ Y/Y)Accumulated othercomprehensive income (loss)-$73K Additional paid-in capital$240,113K (25.57%↑ Y/Y)Royalty obligation -related party$32,076K (0.00%↑ Y/Y)Total currentliabilities$8,738K (14.21%↑ Y/Y)Operating leaseliabilities, long-term$1,053K Common stock, 0.0001and 0.0001 par value...$2K (0.00%↑ Y/Y)Accrued expenses andother current...$7,267K (83.00%↑ Y/Y)Accounts payable$1,124K (-69.46%↓ Y/Y)Operating leaseliabilities, current$347K

Kalaris Therapeutics, Inc. (KLRS)

Kalaris Therapeutics, Inc. (KLRS)